[Reversible cardiogenic shock under 5-fluorouracil treatment].
5-fluorouracil, an antimetabolite agent, has been widely used since 1957 for treatment of varied types of cancer such as gastro-intestinal, pancreas, breast, lung, head and neck malignancies. Cardiotoxicity of 5-fluorouracil is rare and was first described in 1975. It can induce severe complications and involve vital prognosis in the short-term. These complications are less known by cardiologists than medical oncologists. The following clinical case represents a potentially serious and rare case of completely reversible cardiogenic shock in a patient with a colo-rectal cancer. A better knowledge of these complications could reduce cases of death by an earlier diagnosis, and a better evaluation of patients with high cardiotoxicity risk.
Bakouboula
B
B
Service de cardiologie, hôpitaux universitaires de Strasbourg CMCO-SIHCUS, France. b.bakou@voila.fr
Morel
O
O
Douchet
M P
MP
Chauvin
M
M
D000230:Adenocarcinoma / Q000188:drug therapy; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002316:Cardiotonic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012770:Shock, Cardiogenic / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D002316:Cardiotonic Agents; D004280:Dobutamine; D005472:Fluorouracil; D004298:Dopamine